151
|
Wei W, Keogh MJ, Wilson I, Coxhead J, Ryan S, Rollinson S, Griffin H, Kurzawa-Akanbi M, Santibanez-Koref M, Talbot K, Turner MR, McKenzie CA, Troakes C, Attems J, Smith C, Al Sarraj S, Morris CM, Ansorge O, Pickering-Brown S, Ironside JW, Chinnery PF. Mitochondrial DNA point mutations and relative copy number in 1363 disease and control human brains. Acta Neuropathol Commun 2017; 5:13. [PMID: 28153046 PMCID: PMC5290662 DOI: 10.1186/s40478-016-0404-6] [Citation(s) in RCA: 72] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2016] [Accepted: 12/13/2016] [Indexed: 11/10/2022] Open
Abstract
Mitochondria play a key role in common neurodegenerative diseases and contain their own genome: mtDNA. Common inherited polymorphic variants of mtDNA have been associated with several neurodegenerative diseases, and somatic deletions of mtDNA have been found in affected brain regions. However, there are conflicting reports describing the role of rare inherited variants and somatic point mutations in neurodegenerative disorders, and recent evidence also implicates mtDNA levels. To address these issues we studied 1363 post mortem human brains with a histopathological diagnosis of Parkinson's disease (PD), Alzheimer's disease (AD), Frontotemporal dementia - Amyotrophic Lateral Sclerosis (FTD-ALS), Creutzfeldt Jacob disease (CJD), and healthy controls. We obtained high-depth whole mitochondrial genome sequences using off target reads from whole exome sequencing to determine the association of mtDNA variation with the development and progression of disease, and to better understand the development of mtDNA mutations and copy number in the aging brain. With this approach, we found a surprisingly high frequency of heteroplasmic mtDNA variants in 32.3% of subjects. However, we found no evidence of an association between rare inherited variants of mtDNA or mtDNA heteroplasmy and disease. In contrast, we observed a reduction in the amount of mtDNA copy in both AD and CJD. Based on these findings, single nucleotide variants of mtDNA are unlikely to play a major role in the pathogenesis of these neurodegenerative diseases, but mtDNA levels merit further investigation.
Collapse
|
152
|
Dölle C, Flønes I, Nido GS, Miletic H, Osuagwu N, Kristoffersen S, Lilleng PK, Larsen JP, Tysnes OB, Haugarvoll K, Bindoff LA, Tzoulis C. Defective mitochondrial DNA homeostasis in the substantia nigra in Parkinson disease. Nat Commun 2016; 7:13548. [PMID: 27874000 PMCID: PMC5121427 DOI: 10.1038/ncomms13548] [Citation(s) in RCA: 175] [Impact Index Per Article: 21.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2016] [Accepted: 10/13/2016] [Indexed: 02/01/2023] Open
Abstract
Increased somatic mitochondrial DNA (mtDNA) mutagenesis causes premature aging in mice, and mtDNA damage accumulates in the human brain with aging and neurodegenerative disorders such as Parkinson disease (PD). Here, we study the complete spectrum of mtDNA changes, including deletions, copy-number variation and point mutations, in single neurons from the dopaminergic substantia nigra and other brain areas of individuals with Parkinson disease and neurologically healthy controls. We show that in dopaminergic substantia nigra neurons of healthy individuals, mtDNA copy number increases with age, maintaining the pool of wild-type mtDNA population in spite of accumulating deletions. This upregulation fails to occur in individuals with Parkinson disease, however, resulting in depletion of the wild-type mtDNA population. By contrast, neuronal mtDNA point mutational load is not increased in Parkinson disease. Our findings suggest that dysregulation of mtDNA homeostasis is a key process in the pathogenesis of neuronal loss in Parkinson disease.
Collapse
Affiliation(s)
- Christian Dölle
- Department of Neurology, Haukeland University Hospital, 5021 Bergen, Norway.,Department of Clinical Medicine, University of Bergen, 5020 Bergen, Norway
| | - Irene Flønes
- Department of Neurology, Haukeland University Hospital, 5021 Bergen, Norway.,Department of Clinical Medicine, University of Bergen, 5020 Bergen, Norway
| | - Gonzalo S Nido
- Department of Neurology, Haukeland University Hospital, 5021 Bergen, Norway.,Department of Clinical Medicine, University of Bergen, 5020 Bergen, Norway
| | - Hrvoje Miletic
- Department of Pathology, Haukeland University Hospital, 5021 Bergen, Norway.,Department of Biomedicine, University of Bergen, 5020 Bergen, Norway
| | - Nelson Osuagwu
- Department of Neurology, Haukeland University Hospital, 5021 Bergen, Norway.,Department of Clinical Medicine, University of Bergen, 5020 Bergen, Norway
| | - Stine Kristoffersen
- Department of Pathology, Haukeland University Hospital, 5021 Bergen, Norway.,Gade Laboratory for Pathology, Department of Clinical Medicine, Haukeland University Hospital and University of Bergen, 5021 Bergen, Norway
| | - Peer K Lilleng
- Department of Pathology, Haukeland University Hospital, 5021 Bergen, Norway.,Gade Laboratory for Pathology, Department of Clinical Medicine, Haukeland University Hospital and University of Bergen, 5021 Bergen, Norway
| | - Jan Petter Larsen
- Network for Medical Sciences, University of Stavanger, 4036 Stavanger, Norway
| | - Ole-Bjørn Tysnes
- Department of Neurology, Haukeland University Hospital, 5021 Bergen, Norway.,Department of Clinical Medicine, University of Bergen, 5020 Bergen, Norway
| | - Kristoffer Haugarvoll
- Department of Neurology, Haukeland University Hospital, 5021 Bergen, Norway.,Department of Clinical Medicine, University of Bergen, 5020 Bergen, Norway
| | - Laurence A Bindoff
- Department of Neurology, Haukeland University Hospital, 5021 Bergen, Norway.,Department of Clinical Medicine, University of Bergen, 5020 Bergen, Norway
| | - Charalampos Tzoulis
- Department of Neurology, Haukeland University Hospital, 5021 Bergen, Norway.,Department of Clinical Medicine, University of Bergen, 5020 Bergen, Norway
| |
Collapse
|
153
|
Marsh AG, Cottrell MT, Goldman MF. Epigenetic DNA Methylation Profiling with MSRE: A Quantitative NGS Approach Using a Parkinson's Disease Test Case. Front Genet 2016; 7:191. [PMID: 27853465 PMCID: PMC5090125 DOI: 10.3389/fgene.2016.00191] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2016] [Accepted: 10/14/2016] [Indexed: 11/22/2022] Open
Abstract
Epigenetics is a rapidly developing field focused on deciphering chemical fingerprints that accumulate on human genomes over time. As the nascent idea of precision medicine expands to encompass epigenetic signatures of diagnostic and prognostic relevance, there is a need for methodologies that provide high-throughput DNA methylation profiling measurements. Here we report a novel quantification methodology for computationally reconstructing site-specific CpG methylation status from next generation sequencing (NGS) data using methyl-sensitive restriction endonucleases (MSRE). An integrated pipeline efficiently incorporates raw NGS metrics into a statistical discrimination platform to identify functional linkages between shifts in epigenetic DNA methylation and disease phenotypes in samples being analyzed. In this pilot proof-of-concept study we quantify and compare DNA methylation in blood serum of individuals with Parkinson's Disease relative to matched healthy blood profiles. Even with a small study of only six samples, a high degree of statistical discrimination was achieved based on CpG methylation profiles between groups, with 1008 statistically different CpG sites (p < 0.0025, after false discovery rate correction). A methylation load calculation was used to assess higher order impacts of methylation shifts on genes and pathways and most notably identified FGF3, FGF8, HTT, KMTA5, MIR8073, and YWHAG as differentially methylated genes with high relevance to Parkinson's Disease and neurodegeneration (based on PubMed literature citations). Of these, KMTA5 is a histone methyl-transferase gene and HTT is Huntington Disease Protein or Huntingtin, for which there are well established neurodegenerative impacts. The future need for precision diagnostics now requires more tools for exploring epigenetic processes that may be linked to cellular dysfunction and subsequent disease progression.
Collapse
Affiliation(s)
- Adam G Marsh
- Center for Bioinformatics and Computational Biology, Delaware Biotechnology Institute, University of DelawareNewark, DE, USA; Genome Profiling LLC, Helen F. Graham Cancer Center and Research Institute, Center for Translational Cancer ResearchNewark, DE USA; Marine Biosciences, School of Marine Science and Policy, University of DelawareLewes, DE, USA
| | - Matthew T Cottrell
- Genome Profiling LLC, Helen F. Graham Cancer Center and Research Institute, Center for Translational Cancer ResearchNewark, DE USA; Marine Biosciences, School of Marine Science and Policy, University of DelawareLewes, DE, USA
| | - Morton F Goldman
- Genome Profiling LLC, Helen F. Graham Cancer Center and Research Institute, Center for Translational Cancer Research Newark, DE USA
| |
Collapse
|
154
|
Pyle A, Lowes H, Brennan R, Kurzawa-Akanbi M, Yarnall A, Burn D, Hudson G. Reduced mitochondrial DNA is not a biomarker of depression in Parkinson's disease. Mov Disord 2016; 31:1923-1924. [PMID: 27753152 DOI: 10.1002/mds.26825] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2016] [Revised: 09/06/2016] [Accepted: 09/09/2016] [Indexed: 10/20/2022] Open
Affiliation(s)
- Angela Pyle
- Mitochondrial Research Group, University of Newcastle Upon Tyne, Newcastle Upon Tyne, United Kingdom
| | - Hannah Lowes
- Mitochondrial Research Group, University of Newcastle Upon Tyne, Newcastle Upon Tyne, United Kingdom
| | - Rebecca Brennan
- Mitochondrial Research Group, University of Newcastle Upon Tyne, Newcastle Upon Tyne, United Kingdom
| | - Marzena Kurzawa-Akanbi
- Mitochondrial Research Group, University of Newcastle Upon Tyne, Newcastle Upon Tyne, United Kingdom
| | - Alison Yarnall
- Insitutute of Neuroscience, University of Newcastle Upon Tyne, Newcastle Upon Tyne, United Kingdom
| | - David Burn
- Insitutute of Neuroscience, University of Newcastle Upon Tyne, Newcastle Upon Tyne, United Kingdom
| | - Gavin Hudson
- Mitochondrial Research Group, University of Newcastle Upon Tyne, Newcastle Upon Tyne, United Kingdom
| |
Collapse
|
155
|
Altered Striatocerebellar Metabolism and Systemic Inflammation in Parkinson's Disease. OXIDATIVE MEDICINE AND CELLULAR LONGEVITY 2016; 2016:1810289. [PMID: 27688826 PMCID: PMC5023825 DOI: 10.1155/2016/1810289] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/04/2016] [Revised: 06/24/2016] [Accepted: 07/25/2016] [Indexed: 12/26/2022]
Abstract
Parkinson's disease (PD) is the most second common neurodegenerative movement disorder. Neuroinflammation due to systemic inflammation and elevated oxidative stress is considered a major factor promoting the pathogenesis of PD, but the relationship of structural brain imaging parameters to clinical inflammatory markers has not been well studied. Our aim was to evaluate the association of magnetic resonance spectroscopy (MRS) measures with inflammatory markers. Blood samples were collected from 33 patients with newly diagnosed PD and 30 healthy volunteers. MRS data including levels of N-acetylaspartate (NAA), creatine (Cre), and choline (Cho) were measured in the bilateral basal ganglia and cerebellum. Inflammatory markers included plasma nuclear DNA, plasma mitochondrial DNA, and apoptotic leukocyte levels. The Cho/Cre ratio in the dominant basal ganglion, the dominant basal ganglia to cerebellum ratios of two MRS parameters NAA/Cre and Cho/Cre, and levels of nuclear DNA, mitochondrial DNA, and apoptotic leukocytes were significantly different between PD patients and normal healthy volunteers. Significant positive correlations were noted between MRS measures and inflammatory marker levels. In conclusion, patients with PD seem to have abnormal levels of inflammatory markers in the peripheral circulation and deficits in MRS measures in the dominant basal ganglion and cerebellum.
Collapse
|
156
|
Emerging (and converging) pathways in Parkinson's disease: keeping mitochondrial wellness. Biochem Biophys Res Commun 2016; 483:1020-1030. [PMID: 27581196 DOI: 10.1016/j.bbrc.2016.08.153] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2016] [Revised: 08/25/2016] [Accepted: 08/27/2016] [Indexed: 12/31/2022]
Abstract
The selective cell loss in the ventral component of the substantia nigra pars compacta and the presence of alpha-synuclein (α-syn)-rich intraneuronal inclusions called Lewy bodies are the pathological hallmarks of Parkinson's disease (PD), the most common motor system disorder whose aetiology remains largely elusive. Although most cases of PD are idiopathic, there are rare familial forms of the disease that can be traced to single gene mutations that follow Mendelian inheritance pattern. The study of several nuclear encoded proteins whose mutations are linked to the development of autosomal recessive and dominant forms of familial PD enhanced our understanding of biochemical and cellular mechanisms contributing to the disease and suggested that many signs of neurodegeneration result from compromised mitochondrial function. Here we present an overview of the current understanding of PD-related mitochondrial dysfunction including defects in bioenergetics and Ca2+ homeostasis, mitochondrial DNA mutations, altered mitochondrial dynamics and autophagy. We emphasize, in particular, the convergence of many "apparently" different pathways towards a common route involving mitochondria. Understanding whether mitochondrial dysfunction in PD represents the cause or the consequence of the disease is challenging and will help to define the pathogenic processes at the basis of the PD onset and progression.
Collapse
|
157
|
Wernick RI, Estes S, Howe DK, Denver DR. Paths of Heritable Mitochondrial DNA Mutation and Heteroplasmy in Reference and gas-1 Strains of Caenorhabditis elegans. Front Genet 2016; 7:51. [PMID: 27148352 PMCID: PMC4829587 DOI: 10.3389/fgene.2016.00051] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2016] [Accepted: 03/21/2016] [Indexed: 11/17/2022] Open
Abstract
Heteroplasmy—the presence of more than one mitochondrial DNA (mtDNA) sequence type in a cell, tissue, or individual—impacts human mitochondrial disease and numerous aging-related syndromes. Understanding the trans-generational dynamics of mtDNA is critical to understanding the underlying mechanisms of mitochondrial disease and evolution. We investigated mtDNA mutation and heteroplasmy using a set of wild-type (N2 strain) and mitochondrial electron transport chain (ETC) mutant (gas-1) mutant Caenorhabditis elegans mutation-accumulation (MA) lines. The N2 MA lines, derived from a previous experiment, were bottlenecked for 250 generations. The gas-1 MA lines were created for this study, and bottlenecked in the laboratory for up to 50 generations. We applied Illumina-MiSeq DNA sequencing to L1 larvae from five gas-1 MA lines and five N2 MA lines to detect and characterize mtDNA mutation and heteroplasmic inheritance patterns evolving under extreme drift. mtDNA copy number increased in both sets of MA lines: three-fold on average among the gas-1 MA lines and five-fold on average among N2 MA lines. Eight heteroplasmic single base substitution polymorphisms were detected in the gas-1 MA lines; only one was observed in the N2 MA lines. Heteroplasmy frequencies ranged broadly in the gas-1 MA lines, from as low as 2.3% to complete fixation (homoplasmy). An initially low-frequency (<5%) heteroplasmy discovered in the gas-1 progenitor was observed to fix in one gas-1 MA line, achieve higher frequency (37.4%) in another, and be lost in the other three lines. A similar low-frequency heteroplasmy was detected in the N2 progenitor, but was lost in all five N2 MA lines. We identified three insertion-deletion (indel) heteroplasmies in gas-1 MA lines and six indel variants in the N2 MA lines, most occurring at homopolymeric nucleotide runs. The observed bias toward accumulation of single nucleotide polymorphisms in gas-1 MA lines is consistent with the idea that impaired mitochondrial activity renders mtDNA more vulnerable to this type of mutation. The consistent increases in mtDNA copy number implies that extreme genetic drift provides a permissive environment for elevated organelle genome copy number in C. elegans reference and gas-1 strains. This study broadens our understanding of the heteroplasmic mitochondrial mutation process in a multicellular model organism.
Collapse
Affiliation(s)
- Riana I Wernick
- Department of Integrative Biology, Oregon State University Corvallis, OR, USA
| | - Suzanne Estes
- Department of Biology, Portland State University Portland, OR, USA
| | - Dana K Howe
- Department of Integrative Biology, Oregon State University Corvallis, OR, USA
| | - Dee R Denver
- Department of Integrative Biology, Oregon State University Corvallis, OR, USA
| |
Collapse
|